Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2024-08-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the third board of directors of Huizhou Jin Hao Medical Technology Co., Ltd. It details the meeting's attendance, procedures, and voting results on several agenda items, including approval of the 2024 semi-annual report and other company matters. The document references the actual semi-annual report being disclosed separately on the Beijing Stock Exchange information platform, indicating this document is not the report itself but a board meeting resolution announcement. The content focuses on board decisions and meeting details rather than financial data or report content. Therefore, this fits the category of Board/Management Information (MANG). The document length is short (1661 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2024-08-27 Chinese
监事会关于调整公司2022年股权激励计划首次及预留授予股票期权行权价格及拟注销2022年股权激励计划部分股票期权的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of a company regarding adjustments and cancellations related to the company's 2022 stock incentive plan. It discusses the adjustment of stock option exercise prices due to dividend distribution and the cancellation of stock options for employees who left the company. The document references regulatory rules and internal company plans but does not contain financial statements or detailed financial performance data. It is a regulatory compliance announcement related to stock incentive plans and internal governance, not a full report or financial statement. The document length is short (1202 characters), and it is an official announcement of supervisory board opinions and approvals. Therefore, it fits best under Regulatory Filings (RNS) as it does not meet criteria for other specific report types like Annual Report, Interim Report, or Capital/Financing Update.
2024-08-27 Chinese
北京大成（广州）律师事务所关于惠州市锦好医疗科技股份有限公司2022年股票期权与限制性股票激励计划注销部分股票期权、调整首次授予及预留授予股票期权行权价格的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 stock option and restricted stock incentive plan of Huizhou Jinhao Medical Technology Co., Ltd. It discusses the cancellation of some stock options and adjustments to the exercise price of initially granted and reserved stock options. The document references relevant laws and regulations, board and shareholder approvals, and detailed legal compliance analysis. It is not a financial report, earnings release, or management discussion, but a legal opinion related to corporate governance and stock incentive plans. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal filing that does not fit other specific categories like Remuneration Information or Board/Management Information. The document length (7128 characters) and detailed legal content support this classification.
2024-08-27 Chinese
第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Huizhou Jin Hao Medical Technology Co., Ltd. It details the meeting date, attendance, and voting results on several proposals, including approval of the 2024 semi-annual report and related matters. The document references the actual 2024 semi-annual report and other announcements published separately on the Beijing Stock Exchange information disclosure platform, indicating this document itself is not the report but a meeting resolution about it. The document is short (1310 characters) and serves as an official announcement of meeting decisions rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice.
2024-08-27 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report". It covers the financial and operational performance for the period from January 1, 2024 to June 30, 2024, including detailed financial data such as revenue, profit, assets, liabilities, and segment analysis. The document contains comprehensive financial statements and management discussion of business conditions and risks. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '半年度报告摘要' which translates to 'Half-Year Report Summary' for the year 2024. It contains detailed financial data for the half-year period, including assets, liabilities, revenues, profits, and shareholder information. The document explicitly states it is a summary derived from the full half-year report and includes substantive financial data and analysis for the reporting period. It is not merely an announcement or a certification but contains actual financial figures and business descriptions. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is about 4984 characters, which is sufficient to contain substantive financial data, and it is not just a brief announcement or a certification letter. Hence, the classification is IR with high confidence. H1 2024
2024-08-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.